Jianfeng Pharmaceutical has made clear its key work in the new year.
Release time:
2023-02-22
2022 held on February 19 , Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, and Huang Jinlongfen, deputy general manager of the group company and general manager of the pharmaceutical company, made arrangements for the key work of pharmaceutical company 2023 and put forward specific requirements. 2023 With the adjustment of the national epidemic control policy, the domestic into the post-epidemic period, the pharmaceutical company will focus on
"to reduce the first, innovation-oriented, marketing-led, standardized and efficient " work policy, and solidly promote the production and operation management work. In terms of market expansion, the pharmaceutical industry should optimize management and business teams, strengthen process control, purify the market environment, cultivate benchmark markets, and expand Internet marketing; pharmaceutical business should give full play to regional advantages, make full use of government resources, and expand and strengthen subdivision areas; pharmaceutical retail should comply with changes in the market and customer needs, and seek breakthroughs in business philosophy and business ideas; natural products companies continue to give full play to their advantages in quality, technology, information and brand, expand new areas of the market, focus on the development of the domestic ordinary food market, maintain a steady growth in sales volume, and increase the added value of products; Shanghai Beika should find out the changing law of the pesticide market, expand the sales of pesticide products at the best price, and strive to strengthen cooperation with pharmaceutical R & D and production enterprises to achieve differentiated sales.
In terms of new drug development, continue to strengthen communication and coordination between various levels and departments; strengthen communication with drug review and approval departments to improve the speed and success rate of new drug approval; strengthen in-depth cooperation with
CROCompany to improve new drug research and development capabilities; scientifically formulate product development plans, further clarify the responsibilities of development, production and quality departments, and accelerate the speed of new drug research and development; continue to carry out technical research, continuously optimize process parameters, improve yield, continue to introduce varieties of raw material preparation integration, stimulate the potential of API bases and preparation internationalization projects, increase the introduction and development efforts, enrich the enterprise product line. In terms of the construction and technological transformation of the project, make preparations for the international project to meet the
FDAon-site inspection. Complete all kinds of acceptance of various construction projects and relevant approval work before putting them into production, and reach the production standard as soon as possible. Increase foreign cooperation, give full play to the advantages of production capacity and increase revenue; Continue to promote various informatization work and continuously improve the informatization and intelligence level of enterprises. In terms of cost control, further optimize the synthesis process of bulk drugs and improve the yield; Further strengthen the control of the preparation production process; Strengthen the coordination of production and marketing, optimize the production organization mode, and reasonably arrange the production cycle; Speed up the work process of photovoltaic power generation projects; Reasonable deployment of personnel to improve work efficiency; Reduce procurement costs and ensure stable supply by increasing suppliers of raw and auxiliary packaging materials.
In terms of internal control management, we will continue to improve the internal control system of the enterprise, improve the operability of the internal control system, and increase the intensity of system assessment; continue to strengthen tax planning and communicate with the tax authorities to keep abreast of policy developments and reduce the risk of tax inspection.
In terms of safety and environmental protection, take the implementation of the new safety production law as an opportunity to increase the publicity and education of laws and regulations; standardize the development of various production and business activities to ensure the safety of personnel and property. In terms of product quality,
, further strengthen self-inspection of
GMPand GSP , discover potential quality hazards in time, and implement responsibilities; Taking the opportunity of international projects receiving US FDA certification, strengthen staff education and training, and improve professional skills and professional work ability; Attach great importance to pharmacovigilance and adverse reaction monitoring; Strengthen the construction of quality management system, further standardize quality management and quality control behavior. In terms of team building, we should attach importance to the introduction, training and use of talents, so as to provide more platforms for the growth of talents; select young cadres to enrich the management teams at all levels, enhance the vitality of the team, and create a well-trained, dedicated staff team and a United, pragmatic, responsible and capable management team, so as to meet the needs of sustainable development of enterprises. (Reporter
Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31